Monoclonal antibodyFDA-approvedFirst-line
Pertuzumab
How it works
Blocks the HER2 receptor on cancer cells, preventing them from receiving growth signals.
Cancer types
Breast Cancer— HER2-positive
Efficacy
When combined with trastuzumab and chemotherapy, pertuzumab improved progression-free survival in HER2-positive patients by approximately 6 months.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Pertuzumab and Trastuzumab as Neoadjuvant Treatment for HER2-Positive Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Testing a New Imaging Agent for Cancer | Breast Cancer | phase-1 | — | Source → |
| Comparing Treatments for HER2+ Early Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Testing Radiation Therapy with Trastuzumab/Pertuzumab for HER2+ Breast Leptomeningeal Disease | Breast Cancer | phase-1 | — | Source → |
| Trastuzumab and Pertuzumab Transfer into Breast Milk | Breast Cancer | observational | — | Source → |
| Study Compares Two Treatments for HER2-Positive Breast Cancer | Breast Cancer | observational | Pyrotinib provided a progression-free survival benefit of 23.6 months compared to 17.3 months for pertuzumab after adjusting for confounding factors. | Source → |
| Testing a Combination of Medications for HER2-Positive Early-Stage Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Durvalumab, Trastuzumab, and Pertuzumab in HER2-Enriched Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Study of Tucatinib and Trastuzumab-Pertuzumab for Metastatic HER2+ Breast Cancer | Breast Cancer | phase-3 | — | Source → |
| Real-world Study of a Breast Cancer Treatment | Breast Cancer | preclinical | — | Source → |
| Testing T-DM1 and Pertuzumab in Early-Stage HER2+ Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Study of Atezolizumab, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer with Brain Metastases | Breast Cancer | phase-2 | — | Source → |
| Pertuzumab and Trastuzumab Combination Shows Promise in Urothelial Cancer | Ovarian Cancer | phase-2 | The disease control rate was 37% in the urothelial cancer cohort. | Source → |
| Pertuzumab Improves Cancer Treatment Response in Early HER2+ Breast Cancer | Breast Cancer | meta-analysis | The pooled odds ratio showed significantly higher pathological complete response rates with dual HER2 blockade (OR: 1.81; 95% CI: 1.56-2.09) | Source → |
| Dual HER2 Blockade Improves Outcomes in HER2-Positive Breast Cancer | Breast Cancer | meta-analysis | The P + H arm showed significant improvements in 3-year EFS rate (RR 1.08, 95% CI 1.00-1.16, p = 0.04), 5-year EFS rate (RR 1.10, 95% CI 1.01-1.20, p = 0.03), and 5-year DFS rate (RR 1.09, 95% CI 0.99-1.20). | Source → |
| Subcutaneous Trastuzumab/Pertuzumab Shortens Patient Treatment Time | Breast Cancer | phase-2 | SC administration of HP shortened patient time burden by approximately 1 hour. | Source → |
| Reducing Chemotherapy in HER2-Positive Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada | Breast Cancer | review | — | Source → |
| Researchers Respond to Criticism of Neoadjuvant Pertuzumab Study | Breast Cancer | review | — | Source → |
| No Chemotherapy Needed for Some Early-Stage Breast Cancer Patients | Breast Cancer | phase-2 | 37.9% of participants achieved a disappearance of all invasive cancer in the breast and axillary lymph nodes. | Source → |
| Pertuzumab and Trastuzumab Plus Chemotherapy for Metastatic Breast Cancer | Breast Cancer | observational | The median overall survival was 14.9 months longer in patients receiving pertuzumab compared to control patients. | Source → |
| New Treatment Combination for Brain Metastases in HER2-Positive Breast Cancer | Breast Cancer | phase-2 | The CNS objective response rate was 11% (95% CI, 3 to 25), with four partial responses (median duration of response, 4.6 months). | Source → |
| Pertuzumab Improves Survival in Early HER2-Positive Breast Cancer | Breast Cancer | phase-3 | Six-year invasive disease-free survival was 91% and 88% for pertuzumab and placebo groups, respectively. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.